BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 38553731)

  • 1. Evaluating hepatitis C cascade of care surveillance system in Tuscany, Italy, through a population retrospective data-linkage study, 2015-2021.
    Ceccarelli L; Moretti G; Mazzilli S; Petri D; Corazza I; Rizzo C; Lucenteforte E; Vainieri M; Seghieri C; Tavoschi L;
    BMC Infect Dis; 2024 Mar; 24(1):362. PubMed ID: 38553731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined treatment and prevention strategies for hepatitis C virus elimination in the prisons in New South Wales: a modelling study.
    Bretaña NA; Gray RR; Cunningham EB; Betz-Stablein B; Ribeiro R; Graw F; Luciani F; Lloyd AR
    Addiction; 2020 May; 115(5):901-913. PubMed ID: 31633853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. On-site testing and case management to improve hepatitis C care in drug users: a prospective, longitudinal, multicenter study in the DAA era.
    Busschots D; Bielen R; Koc ÖM; Heyens L; Dercon E; Verrando R; Janssens F; Van den Bergh L; Van Lint P; Bruckers L; Nevens F; Robaeys G
    BMC Public Health; 2021 Aug; 21(1):1574. PubMed ID: 34416867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. "I want to get better, but…": identifying the perceptions and experiences of people who inject drugs with respect to evolving hepatitis C virus treatments.
    Goodyear T; Brown H; Browne AJ; Hoong P; Ti L; Knight R
    Int J Equity Health; 2021 Mar; 20(1):81. PubMed ID: 33740984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic Hepatitis C Cascade of Care in Prisoners-Is There Still Some Work to Do? Analysis of Two Large Penitentiaries in Northern Italy.
    Cambianica A; Marchese V; Pennati F; Faustinelli A; Migliorati M; Roda F; Spinetti A; Zaltron S; Fiorentini S; Caruso A; Quiros-Roldan E; Castelli F; Focà E
    Int J Environ Res Public Health; 2024 Jan; 21(1):. PubMed ID: 38248566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Planning the hepatitis C virus elimination in Cyprus: A modeling study.
    Gountas I; Yiasemi I; Kyprianou E; Mina C; Georgiou C; Katsioloudes P; Kouroufexi A; Demetriou A; Xenofontos E; Nikolopoulos G
    World J Gastroenterol; 2021 Aug; 27(31):5219-5231. PubMed ID: 34497446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model.
    Heffernan A; Cooke GS; Nayagam S; Thursz M; Hallett TB
    Lancet; 2019 Mar; 393(10178):1319-1329. PubMed ID: 30704789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in incidence of hepatitis C virus reinfection and access to direct-acting antiviral therapies in people with HIV from six countries, 2010-19: an analysis of data from a consortium of prospective cohort studies.
    Sacks-Davis R; van Santen DK; Boyd A; Young J; Stewart A; Doyle JS; Rauch A; Mugglin C; Klein M; van der Valk M; Smit C; Jarrin I; Berenguer J; Lacombe K; Requena MB; Wittkop L; Leleux O; Bonnet F; Salmon D; Matthews GV; Guy R; Martin NK; Spelman T; Prins M; Stoove M; Hellard M;
    Lancet HIV; 2024 Feb; 11(2):e106-e116. PubMed ID: 38224708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population-level estimates of hepatitis C reinfection post scale-up of direct-acting antivirals among people who inject drugs.
    Yeung A; Palmateer NE; Dillon JF; McDonald SA; Smith S; Barclay S; Hayes PC; Gunson RN; Templeton K; Goldberg DJ; Hickman M; Hutchinson SJ
    J Hepatol; 2022 Mar; 76(3):549-557. PubMed ID: 34634387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gaps in hepatitis C virus prevention and care for HIV-hepatitis C virus co-infected people who inject drugs in Canada.
    Lanièce Delaunay C; Maheu-Giroux M; Marathe G; Saeed S; Martel-Laferrière V; Cooper CL; Walmsley S; Cox J; Wong A; Klein MB;
    Int J Drug Policy; 2022 May; 103():103627. PubMed ID: 35218989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A 'one-stop-shop' point-of-care hepatitis C RNA testing intervention to enhance treatment uptake in a reception prison: The PIVOT study.
    Sheehan Y; Cunningham EB; Cochrane A; Byrne M; Brown T; McGrath C; Lafferty L; Tedla N; Dore GJ; Lloyd AR; Grebely J
    J Hepatol; 2023 Sep; 79(3):635-644. PubMed ID: 37116714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. "Everybody living with a chronic disease is entitled to be cured": Challenges and opportunities in scaling up access to direct-acting antiviral hepatitis C virus treatment among people who inject drugs.
    Goodyear T; Ti L; Carrieri P; Small W; Knight R
    Int J Drug Policy; 2020 Jul; 81():102766. PubMed ID: 32416525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Global cascade of care for chronic hepatitis C virus infection: A systematic review and meta-analysis.
    Yousafzai MT; Bajis S; Alavi M; Grebely J; Dore GJ; Hajarizadeh B
    J Viral Hepat; 2021 Oct; 28(10):1340-1354. PubMed ID: 34310812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Setting foot in private spaces: extending the hepatitis C cascade of care to automatic needle/syringe dispensing machines, a mixed methods study.
    Coupland H; Henderson C; Pritchard-Jones J; Kao SC; Sheils S; Nagy R; O'Donnell M; Haber PS; Day CA
    Harm Reduct J; 2022 May; 19(1):56. PubMed ID: 35643528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interventions to enhance testing and linkage to treatment for hepatitis C infection for people who inject drugs: A systematic review and meta-analysis.
    Cunningham EB; Wheeler A; Hajarizadeh B; French CE; Roche R; Marshall AD; Fontaine G; Conway A; Bajis S; Valencia BM; Presseau J; Ward JW; Degenhardt L; Dore GJ; Hickman M; Vickerman P; Grebely J
    Int J Drug Policy; 2023 Jan; 111():103917. PubMed ID: 36542883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment access is only the first step to hepatitis C elimination: experience of universal anti-viral treatment access in Australia.
    Doyle JS; Scott N; Sacks-Davis R; Pedrana AE; Thompson AJ; Hellard ME;
    Aliment Pharmacol Ther; 2019 May; 49(9):1223-1229. PubMed ID: 30908706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The civil society monitoring of hepatitis C response related to the WHO 2030 elimination goals in 35 European countries.
    Maticic M; Pirnat Z; Leicht A; Zimmermann R; Windelinck T; Jauffret-Roustide M; Duffell E; Tammi T; Schatz E
    Harm Reduct J; 2020 Nov; 17(1):89. PubMed ID: 33213481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of COVID-19 pandemic on the 2020 hepatitis C cascade of care in the Republic of Georgia.
    Gamkrelidze A; Handanagic S; Shadaker S; Turdziladze A; Tsereteli M; Getia V; Aslanikashvili A; Surguladze S; Gvinjilia L; Kuchuloria T; Tskhomelidze I; Armstrong PA
    Public Health; 2022 Apr; 205():182-186. PubMed ID: 35305459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrating Management of Hepatitis C Infection into Primary Care: the Key to Hepatitis C Elimination Efforts.
    Wang AE; Hsieh E; Turner BJ; Terrault N
    J Gen Intern Med; 2022 Oct; 37(13):3435-3443. PubMed ID: 35484367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. From Prioritization to Universal Treatment: Successes and Challenges of Hepatitis C Virus Elimination in Italy.
    Kondili LA; Craxì L; Nava F; Babudieri S; D'Ambrosio R; Marcellusi A; Mennini FS; Valle S; Russo P; Olimpieri PP; Andreoni M; Aghemo A
    J Infect Dis; 2023 Sep; 228(Suppl 3):S211-S220. PubMed ID: 37703346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.